Skip to main page content
Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

My NCBI Filters
Results by year

Table representation of search results timeline featuring number of search results per year.

Year Number of Results
1986 1
1988 2
1989 4
1990 1
1992 2
1994 2
1995 2
1996 1
1999 1
2000 1
2003 3
2004 2
2005 2
2006 1
2007 1
2008 1
2014 1
2016 1
2020 3
2021 2
Text availability
Article attribute
Article type
Publication date

Search Results

32 results
Results by year
Filters applied: . Clear all
Page 1
PD-1 Blockade with Pembrolizumab in Advanced Merkel-Cell Carcinoma.
Nghiem PT, Bhatia S, Lipson EJ, Kudchadkar RR, Miller NJ, Annamalai L, Berry S, Chartash EK, Daud A, Fling SP, Friedlander PA, Kluger HM, Kohrt HE, Lundgren L, Margolin K, Mitchell A, Olencki T, Pardoll DM, Reddy SA, Shantha EM, Sharfman WH, Sharon E, Shemanski LR, Shinohara MM, Sunshine JC, Taube JM, Thompson JA, Townson SM, Yearley JH, Topalian SL, Cheever MA. Nghiem PT, et al. Among authors: chartash ek. N Engl J Med. 2016 Jun 30;374(26):2542-52. doi: 10.1056/NEJMoa1603702. Epub 2016 Apr 19. N Engl J Med. 2016. PMID: 27093365 Free PMC article. Clinical Trial.
Adalimumab, a fully human anti-tumor necrosis factor alpha monoclonal antibody, for the treatment of rheumatoid arthritis in patients taking concomitant methotrexate: the ARMADA trial.
Weinblatt ME, Keystone EC, Furst DE, Moreland LW, Weisman MH, Birbara CA, Teoh LA, Fischkoff SA, Chartash EK. Weinblatt ME, et al. Among authors: chartash ek. Arthritis Rheum. 2003 Jan;48(1):35-45. doi: 10.1002/art.10697. Arthritis Rheum. 2003. PMID: 12528101 Free article. Clinical Trial.
Radiographic, clinical, and functional outcomes of treatment with adalimumab (a human anti-tumor necrosis factor monoclonal antibody) in patients with active rheumatoid arthritis receiving concomitant methotrexate therapy: a randomized, placebo-controlled, 52-week trial.
Keystone EC, Kavanaugh AF, Sharp JT, Tannenbaum H, Hua Y, Teoh LS, Fischkoff SA, Chartash EK. Keystone EC, et al. Among authors: chartash ek. Arthritis Rheum. 2004 May;50(5):1400-11. doi: 10.1002/art.20217. Arthritis Rheum. 2004. PMID: 15146409 Free article. Clinical Trial.
Adalimumab, a fully human anti tumor necrosis factor-alpha monoclonal antibody, and concomitant standard antirheumatic therapy for the treatment of rheumatoid arthritis: results of STAR (Safety Trial of Adalimumab in Rheumatoid Arthritis).
Furst DE, Schiff MH, Fleischmann RM, Strand V, Birbara CA, Compagnone D, Fischkoff SA, Chartash EK. Furst DE, et al. Among authors: chartash ek. J Rheumatol. 2003 Dec;30(12):2563-71. J Rheumatol. 2003. PMID: 14719195 Clinical Trial.
Efficacy, pharmacokinetic, and safety assessment of adalimumab, a fully human anti-tumor necrosis factor-alpha monoclonal antibody, in adults with rheumatoid arthritis receiving concomitant methotrexate: a pilot study.
Weisman MH, Moreland LW, Furst DE, Weinblatt ME, Keystone EC, Paulus HE, Teoh LS, Velagapudi RB, Noertersheuser PA, Granneman GR, Fischkoff SA, Chartash EK. Weisman MH, et al. Among authors: chartash ek. Clin Ther. 2003 Jun;25(6):1700-21. doi: 10.1016/s0149-2918(03)80164-9. Clin Ther. 2003. PMID: 12860493 Clinical Trial.
First-in-human phase 1 study of MK-1248, an anti-glucocorticoid-induced tumor necrosis factor receptor agonist monoclonal antibody, as monotherapy or with pembrolizumab in patients with advanced solid tumors.
Geva R, Voskoboynik M, Dobrenkov K, Mayawala K, Gwo J, Wnek R, Chartash E, Long GV. Geva R, et al. Among authors: chartash e. Cancer. 2020 Nov 15;126(22):4926-4935. doi: 10.1002/cncr.33133. Epub 2020 Aug 18. Cancer. 2020. PMID: 32809217 Clinical Trial.
Septic subdeltoid bursitis.
Chartash EK, Good PK, Gould ES, Furie RA. Chartash EK, et al. Semin Arthritis Rheum. 1992 Aug;22(1):25-9. doi: 10.1016/0049-0172(92)90045-f. Semin Arthritis Rheum. 1992. PMID: 1411579 Review.
32 results
You have reached the last page of results. A maximum of 10,000 results are available.
Jump to page